Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) announced the initiation of a Phase I clinical study for its adsorbed diphtheria-tetanus-acellular pertussis (component) and Haemophilus influenzae type b (conjugate) combination vaccine (DTaP-Hib). The independently developed quadrivalent vaccine aims to prevent four pediatric diseases (pertussis, diphtheria, tetanus, Hib infections) while reducing injection burden and improving vaccination compliance in China’s ~15 million annual birth cohort.
Complex multi-dose regimens contribute to drop-out
Strategic Context & Market Opportunity
Factor
Implication
China Pediatric Vaccine Market
RMB 15+ billion annually; combination vaccines preferred by parents and immunization programs for convenience
National Immunization Program (NIP)
DTaP and Hib separately included in expanded NIP; combination products not yet reimbursed – private market opportunity
Zhifei Vaccine Franchise
Established HPV, meningococcal, pneumococcal portfolio; DTaP-Hib adds pediatric core combination to capture birth cohort
Competitive Dynamics
Sanofi Pentaxim (DTaP-IPV-Hib, 5-valent) premium-priced; Zhifei positions as cost-competitive quadrivalent alternative
Manufacturing Scale
Zhifei’s Chongqing facility supports 10+ million dose annual capacity; ready for Phase III scale-up
Development Timeline: Phase I 2026; Phase II immunogenicity/non-inferiority 2027–2028; Phase III efficacy 2029; NDA filing 2030
Commercial Potential: Peak sales RMB 500–800 million annually assuming 15–20% share of private-market pediatric combination vaccines; NIP inclusion would expand to RMB 2+ billion
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase I safety outcomes, immunogenicity profile, and regulatory pathway for Zhifei’s DTaP-Hib quadrivalent vaccine. Actual results may differ due to combination vaccine formulation challenges, competitive dynamics with Sanofi’s pentavalent product, and NIP reimbursement policy decisions.-Fineline Info & Tech
By Fineline Cube